News | January 07, 2023
KIMS invests further in Sarvejana Healthcare
The company now holds 56.61% of the total paid-up equity share capital of Sarvejana Healthcare
The company now holds 56.61% of the total paid-up equity share capital of Sarvejana Healthcare
The unit will have installed manufacturing capacity of over 15 million vials annually that includes lyophilized vials, all in the anti-cancer segment
It ensures sufficient serum estradiol levels to alleviate menopausal symptoms
The strategic acquirer maintains a nationwide presence in the LTC pharmacy space
Krishna Institute of Medical Sciences to consider raising Rs. 300 crores
The term of O&M is for 15 years with a lock in period of 5 years for the Company and 15 years for VHPL & Bharathi Education trust.
Tafasitamab is conditionally approved by both the U.S. Food and Drug Administration and European Medicines Agency
Miravo to remain a Canadian controlled and operated company following closing of the transaction
The scheme is subject to statutory and regulatory approvals as may be necessary.
The product is backed by required scientific proof and comparative bioequivalence studies
Subscribe To Our Newsletter & Stay Updated
